19.01.2011 • NewsAmgenBoehringer Ingelheim

Amgen To Sell California Drug Plant To Boehringer

Amgen, the world's biggest maker of biotechnology drugs, plans to sell its Fremont, Calif., development and manufacturing plant to Germany's Boehringer Ingelheim, the companies said on Tuesday. Financial terms were not disclosed.

Amgen, based in Thousand Oaks, Calif., said the 100,000-square-foot plant employs about 360 people who will become employees of Boehringer.

The German company, which has manufactured Amgen drugs on a contract basis for more than 10 years, said the deal will allow it to expand contract manufacturing, process development and development of active ingredients based on biologics.

The deal is expected to close in March.

Amgen obtained the Fremont facility in its 2006 acquisition of antibody drug maker Abgenix.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.